KalVista Pharmaceuticals Acquired by Chiesi Group for $27.00/Share; Delisting from Nasdaq
Summary
KalVista Pharmaceuticals has completed its acquisition by Chiesi Group for $27.00 per share, resulting in its delisting from Nasdaq and a change of control.
Key Events
-
Acquisition Completed
Chiesi Group successfully completed its tender offer and subsequent merger to acquire KalVista Pharmaceuticals for $27.00 per share in cash. Approximately 77.8% of outstanding shares were tendered.
-
Delisting from Nasdaq
KalVista's common stock ceased trading on The Nasdaq Global Market effective June 11, 2026, and the company will be delisted, terminating its reporting obligations.
-
Change of Control and Board Resignations
KalVista is now a wholly-owned subsidiary of Chiesi Group. All previous directors resigned, and John Hess, from the acquirer, became the sole director and officer.
-
Executive Transaction Bonuses
CEO Benjamin L. Palleiko, CMO Paul Audhya, and CFO Brian Piekos received cash transaction bonuses of $5,070,000, $2,930,000, and $2,500,000, respectively, totaling over $10 million.
Analysis
This 8-K filing confirms the definitive completion of the acquisition of KalVista Pharmaceuticals by Chiesi Group for $27.00 per share. This event fundamentally alters the company's status, as it ceases to be an independent publicly traded entity and will be delisted from Nasdaq. The filing provides critical details on the finalization of the transaction, including the conversion of outstanding shares and convertible notes into cash, the resignation of the entire board, appointment of new leadership, and significant transaction bonuses for key executives.
At the time of this filing, KALV was trading at $27.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.83 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.